Pharmacogenomics of Drug Safety in Multiple Sclerosis

This study is currently recruiting participants.

See

Contacts and Locations

Verified May 2016 by University of British Columbia

Sponsor:

Collaborators:

Canadian Institutes of Health Research (CIHR)

Canada Foundation for Innovation

Genome Canada

British Columbia Clinical Genomics Network

Information provided by (Responsible Party):

University of British Columbia

ClinicalTrials.gov Identifier:

NCT01118130

First received: May 4, 2010

Last updated: May 30, 2016

Last verified: May 2016

History of Changes

Purpose

To investigate whether genotypic differences can be identified between MS patients developing 'liver injury' (defined as ALT levels five times the upper normal limit and above) compared to those not developing liver injury after exposure to beta-interferon for MS.

Condition
Multiple Sclerosis


Study Type:	Observational
Study Design:	Observational Model: Case Control Time Perspective: Retrospective
Official Title:	Canadian Pharmacogenomics Network for Drug Safety: Genetic Factors Associated With Multiple Sclerosis Treatment

Resource links provided by NLM:

Genetics Home Reference related topics: multiple sclerosis

MedlinePlus related topics: Multiple Sclerosis

U.S. FDA Resources

Further study details as provided by University of British Columbia:

Primary Outcome Measures:

Experienced an adverse drug reaction or not? [ Time Frame: No specified time frame ]

Biospecimen Retention: Samples With DNA

Saliva


Estimated Enrollment:	300
Study Start Date:	June 2010
Estimated Study Completion Date:	December 2016
Estimated Primary Completion Date:	December 2016 (Final data collection date for primary outcome measure)

Groups/Cohorts
Case MS patients experiencing an adverse drug reaction to an MS immunomodulatory therapy
Control MS patients not experiencing an adverse drug reaction to an MS immunomodulatory therapy

Detailed Description:

PURPOSE: To investigate whether genotypic differences can be identified between MS patients who develop liver injury compared to those who do not develop injury in response to beta-interferon therapy.

OBJECTIVE: To determine whether elevated liver enzyme tests (ALT > 5 times the upper limit of normal) in response to beta-interferon therapy in MS patients is associated with genetic polymorphisms.

METHOD OF RECRUITMENT:

Patients will be identified through a clinic database and chart reviews. An introductory letter will be mailed to potential participants, inviting them to volunteer. A follow-up phone call will be made to determine interest and consent into study.

PROCEDURES:

Saliva will be collected for genetic analyses and a questionnaire will be administered

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Multiple sclerosis (MS) patients attending MS clinics located at the University of British Columbia Hospital, Winnipeg Health Sciences Centre, Dalhousie (Halifax, Nova Scotia) MS clinic, London Health Sciences Centre (London, ON) and Hôpital Notre-Dame (Montréal). Participants must have definite MS (Poser or McDonald criteria), with a relapsing-remitting or secondary-progressive disease course, registered at one of the above MS Clinics and prescribed a beta-interferon as an immunomodulatory drug for MS.

Criteria

Inclusion Criteria: Cases and controls must have

definite MS (Poser or McDonald criteria)
relapsing-remitting or secondary-progressive disease course
Prescribed a beta-interferon as their immunomodulatory drug for MS

Exclusion Criteria:

primary-progressive MS
an elevated liver test result within 6 months of starting beta-interferon treatment
presence of a co-morbidity that is a known risk-factor for liver injury

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01118130

Contacts


Contact: Jessica Stortz, M.Sc	604-875-2000	jstortz@popi.ubc.ca

Locations


Canada, British Columbia
MS Clinic UBC Hospital	Recruiting
Vancouver, British Columbia, Canada, V6T 2B5
Canada, Manitoba
Winnipeg Health Sciences Centre	Completed
Winnipeg, Manitoba, Canada
Canada, Nova Scotia
Dalhousie MS Research Unit	Enrolling by invitation
Halifax, Nova Scotia, Canada
Canada, Ontario
London Health Sciences Centre MS clinic	Enrolling by invitation
London, Ontario, Canada
Canada, Quebec
Hôpital Notre-Dame MS clinic	Enrolling by invitation
Montréal, Quebec, Canada

Sponsors and Collaborators

University of British Columbia

Canadian Institutes of Health Research (CIHR)

Canada Foundation for Innovation

Genome Canada

British Columbia Clinical Genomics Network

Investigators


Principal Investigator:	Bruce Carleton	University of British Columbia
Study Director:	Michael Hayden	University of British Columbia
Study Director:	Helen Tremlett	University of British Columbia
Study Director:	Anthony Traboulsee	University of British Columbia

More Information


Responsible Party:	University of British Columbia
ClinicalTrials.gov Identifier:	NCT01118130 History of Changes
Other Study ID Numbers:	H10-00494
Study First Received:	May 4, 2010
Last Updated:	May 30, 2016

Keywords provided by University of British Columbia:


Genetics genomics Multiple Sclerosis beta-interferons

Additional relevant MeSH terms:


Sclerosis Multiple Sclerosis Pathologic Processes Demyelinating Autoimmune Diseases, CNS Autoimmune Diseases of the Nervous System	Nervous System Diseases Demyelinating Diseases Autoimmune Diseases Immune System Diseases

ClinicalTrials.gov processed this record on June 23, 2017

To Top